针对接受口服肿瘤药物治疗的癌症患者的支持性干预措施的设计和测试所面临的挑战。
Challenges to the design and testing supportive interventions for cancer patients treated with oral oncolytic agents.
机构信息
College of Nursing, Michigan State University, C346 Bott Building, 1355 Bogue Street, East Lansing, MI, 48824, USA.
University of Michigan, Ann Arbor, MI, USA.
出版信息
Support Care Cancer. 2018 Dec;26(12):3975-3977. doi: 10.1007/s00520-018-4414-8. Epub 2018 Aug 23.
Abstract
Conducting research into supportive care for patients as they initiate treatment with oral oncolytic agents poses numerous new challenges. Some of these medications have very complex dosing schedules and produce symptoms that patients need to manage at home with less reliance on oncology clinicians. We describe lessons learned from a multi-site trial designed to improve adherence to these medications and self-management of symptoms among patients newly prescribed oral oncolytic agents. Identifying these challenges can assist researchers to improve the integrity of their future supportive care trials.
摘要
在患者开始使用口服肿瘤溶解剂进行治疗时，对支持性护理进行研究带来了诸多新的挑战。其中一些药物的剂量方案非常复杂，会产生一些症状，患者需要在家中自行管理，减少对肿瘤学临床医生的依赖。我们描述了从一项旨在提高新处方口服肿瘤溶解剂患者对这些药物的依从性和自我管理症状的多中心试验中吸取的经验教训。识别这些挑战可以帮助研究人员提高他们未来支持性护理试验的完整性。
相似文献
1
Challenges to the design and testing supportive interventions for cancer patients treated with oral oncolytic agents.针对接受口服肿瘤药物治疗的癌症患者的支持性干预措施的设计和测试所面临的挑战。
Support Care Cancer. 2018 Dec;26(12):3975-3977. doi: 10.1007/s00520-018-4414-8. Epub 2018 Aug 23.
2
Oncolytic virotherapy.溶瘤病毒疗法
Ann Hepatol. 2008 Jan-Mar;7(1):34-45.
3
Oncolytic virotherapy of breast cancer.溶瘤病毒治疗乳腺癌。
Gynecol Oncol. 2011 Oct;123(1):164-71. doi: 10.1016/j.ygyno.2011.06.021. Epub 2011 Jul 20.
4
United virus: the oncolytic tag-team against cancer!联合病毒：抗肿瘤的溶瘤联合治疗！
Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):205-11. doi: 10.1016/j.cytogfr.2010.02.008. Epub 2010 Mar 12.
5
[Oncolytic virotherapy: new strategies in oncology].[溶瘤病毒疗法：肿瘤学的新策略]
Orv Hetil. 2007 Oct 28;148(43):2019-26. doi: 10.1556/OH.2007.27970.
6
Do treatment patterns alter beliefs cancer patients hold regarding oral oncolytic agents?治疗模式是否会改变癌症患者对口服肿瘤溶瘤剂的看法？
Psychooncology. 2018 Mar;27(3):1005-1012. doi: 10.1002/pon.4606. Epub 2018 Jan 11.
7
Novel oncolytic viruses: riding high on the next wave?新型溶瘤病毒：在下一波浪潮中高歌猛进？
Cytokine Growth Factor Rev. 2010 Apr-Jun;21(2-3):177-83. doi: 10.1016/j.cytogfr.2010.02.012. Epub 2010 Mar 12.
8
[Current state of oncolytic virotherapy in Japan].[日本溶瘤病毒疗法的现状]
Gan To Kagaku Ryoho. 2013 May;40(5):553-8.
9
Oncolytic virotherapy for oral squamous cell carcinoma using replication-competent viruses.溶瘤病毒治疗口腔鳞状细胞癌的研究进展。
Oral Oncol. 2009 Dec;45(12):1021-7. doi: 10.1016/j.oraloncology.2009.09.002. Epub 2009 Oct 14.
10
Oncolytic virotherapy of gynecologic malignancies.妇科恶性肿瘤的溶瘤病毒治疗。
Gynecol Oncol. 2011 Feb;120(2):302-10. doi: 10.1016/j.ygyno.2010.10.031. Epub 2010 Dec 8.
引用本文的文献
1
An Automated Intervention Did Not Improve Adherence to Oral Oncolytic Agents While Managing Symptoms: Results From a Two-Arm Randomized Controlled Trial.一种自动化干预措施在管理症状的同时并未改善口服肿瘤药物的依从性：来自一项双臂随机对照试验的结果。
J Pain Symptom Manage. 2018 Nov;56(5):727-735. doi: 10.1016/j.jpainsymman.2018.07.021. Epub 2018 Aug 8.
本文引用的文献
1
Mobile Health Intervention to Increase Oral Cancer Therapy Adherence in Patients With Chronic Myeloid Leukemia (The REMIND System): Clinical Feasibility and Acceptability Assessment.提高慢性髓性白血病患者口腔癌治疗依从性的移动健康干预措施（REMIND系统）：临床可行性和可接受性评估
JMIR Mhealth Uhealth. 2017 Dec 6;5(12):e184. doi: 10.2196/mhealth.8349.
2
Raising the Dose and Raising the Cost: The Case of Pembrolizumab in Lung Cancer.提高剂量与增加成本：帕博利珠单抗治疗肺癌的案例
J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx125.
3
A Phamacoeconomic Analysis of Personalized Dosing vs Fixed Dosing of Pembrolizumab in Firstline PD-L1-Positive Non-Small Cell Lung Cancer.帕博利珠单抗一线治疗 PD-L1 阳性非小细胞肺癌的个体化剂量与固定剂量的药物经济学分析。
J Natl Cancer Inst. 2017 Nov 1;109(11). doi: 10.1093/jnci/djx063.
4
How to report adherence to treatment as clinically relevant data-making a case of CML and TKI.如何将治疗依从性报告为具有临床相关性的数据——以慢性粒细胞白血病和酪氨酸激酶抑制剂为例
Support Care Cancer. 2018 Feb;26(2):323-324. doi: 10.1007/s00520-017-3809-2. Epub 2017 Jul 11.
5
Interventions to Improve Oral Chemotherapy Safety and Quality: A Systematic Review.干预措施以提高口服化疗的安全性和质量：系统评价。
JAMA Oncol. 2018 Jan 1;4(1):105-117. doi: 10.1001/jamaoncol.2017.0625.
6
Impact of a specialty pharmacy case management service on adherence in patients receiving oral antineoplastic agents.专科药房病例管理服务对接受口服抗肿瘤药物患者依从性的影响。
J Oncol Pharm Pract. 2018 Jul;24(5):371-378. doi: 10.1177/1078155217708022. Epub 2017 May 16.
7
Mobile Application to Promote Adherence to Oral Chemotherapy and Symptom Management: A Protocol for Design and Development.促进口服化疗依从性和症状管理的移动应用程序：设计与开发方案
JMIR Res Protoc. 2017 Apr 20;6(4):e62. doi: 10.2196/resprot.6198.
8
The Association Between Patient-Reported and Objective Oral Anticancer Medication Adherence Measures: A Systematic Review
.患者报告的与客观的口服抗癌药物依从性测量指标之间的关联：一项系统评价
Oncol Nurs Forum. 2016 Sep 1;43(5):576-82. doi: 10.1188/16.ONF.576-582.
9
Updating the American Society of Clinical Oncology Value Framework: Revisions and Reflections in Response to Comments Received.更新美国临床肿瘤学会价值框架：针对收到的评论进行的修订与思考
J Clin Oncol. 2016 Aug 20;34(24):2925-34. doi: 10.1200/JCO.2016.68.2518. Epub 2016 May 31.
10
Medication adherence to oral anticancer drugs: systematic review.口服抗癌药物的用药依从性：系统评价
Expert Rev Anticancer Ther. 2016;16(4):423-32. doi: 10.1586/14737140.2016.1159515. Epub 2016 Mar 16.
Zotero 插件